Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 44% Improvement Relative Risk Death/hospitalization 20% primary Ventilation 47% Hospitalization 20% c19early.org/o Tardif et al. NCT04322682 COLCORONA Colchicine RCT LATE Is late treatment with colchicine beneficial for COVID-19? Double-blind RCT 4,488 patients in Canada Lower mortality (p=0.3) and death/hosp. (p=0.079), not stat. sig. Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 Favors colchicine Favors control
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (date from earlier preprint), COLCORONA, NCT04322682 (history)
Tardif et al., Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded,.., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (date from earlier preprint), COLCORONA, NCT04322682
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment.
Although the 44% lower mortality is not statistically significant, it is consistent with the significant 35% lower mortality [22‑45%] from meta analysis of the 36 mortality results to date.
risk of death, 43.9% lower, RR 0.56, p = 0.30, treatment 5 of 2,235 (0.2%), control 9 of 2,253 (0.4%), NNT 569, odds ratio converted to relative risk.
risk of death/hospitalization, 20.0% lower, RR 0.80, p = 0.08, treatment 104 of 2,235 (4.7%), control 131 of 2,253 (5.8%), NNT 86, odds ratio converted to relative risk, primary outcome.
risk of mechanical ventilation, 46.8% lower, RR 0.53, p = 0.09, treatment 11 of 2,235 (0.5%), control 21 of 2,253 (0.9%), NNT 227, odds ratio converted to relative risk.
risk of hospitalization, 20.0% lower, RR 0.80, p = 0.09, treatment 101 of 2,235 (4.5%), control 128 of 2,253 (5.7%), NNT 86, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tardif et al., 27 Jan 2021, Double Blind Randomized Controlled Trial, Canada, peer-reviewed, 44 authors, average treatment delay 5.3 days, dosage 1mg days 1-3, 0.5mg days 4-30, trial NCT04322682 (history) (COLCORONA).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Articles Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial Jean-Claude Tardif, Nadia Bouabdallaoui, Philippe L L’Allier, Daniel Gaudet, Binita Shah, Michael H Pillinger, Jose Lopez-Sendon, Protasio da Luz, Lucie Verret, Sylvia Audet, Jocelyn Dupuis, André Denault, Martin Pelletier, Philippe A Tessier, Sarah Samson, Denis Fortin, Jean-Daniel Tardif, David Busseuil, Elisabeth Goulet, Chantal Lacoste, Anick Dubois, Avni Y Joshi, David D Waters, Priscilla Hsue, Norman E Lepor, Frédéric Lesage, Nicolas Sainturet, Eve Roy-Clavel, Zohar Bassevitch, Andreas Orfanos, Gabriela Stamatescu, Jean C Grégoire, Lambert Busque, Christian Lavallée, Pierre-Olivier Hétu, Jean-Sébastien Paquette, Spyridon G Deftereos, Sylvie Levesque, Mariève Cossette, Anna Nozza, Malorie Chabot-Blanchet, Marie-Pierre Dubé, Marie-Claude Guertin, Guy Boivin, for the COLCORONA Investigators* Summary Lancet Respir Med 2021; 9: 924–32 Published Online May 27, 2021 https://doi.org/10.1016/ S2213-2600(21)00222-8 See Comment page 811 *Members listed in the appendix Montreal Heart Institute (Prof J-C Tardif MD, N Bouabdallaoui MD, P L L’Allier MD, L Verret MSc, S Audet MSc, Prof J Dupuis MD, Prof A Denault MD, S Samson BSN, D Fortin BSN, J-D Tardif BSc, D Busseuil PhD, E Goulet RN, C Lacoste DEC, A Dubois PhD, Prof F Lesage PhD, J C Grégoire MD, Prof M-P Dubé PhD), Ecogene-21 (D Gaudet MD), and Department of Medicine (D Gaudet), Université de Montréal, Montreal, QC, Canada; New York University Grossman School of Medicine, New York, NY, USA (B Shah MD, Prof M H Pillinger MD); H La Paz, IdiPaz, UAM, Ciber-CV, Madrid, Spain (Prof J Lopez-Sendon MD); Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil (Prof P da Luz MD); Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada (M Pelletier PhD, P A Tessier PhD, G Boivin MD); Mayo Clinic, Rochester, MN, USA (Prof A Y Joshi MD); San Francisco General Hospital, San Francisco, CA, USA (Prof D D Waters MD, Prof P Hsue MD); Cedars-Sinai Heart Institute, Geffen School of Medicine-UCLA, Los Angeles, CA, USA (Prof N E Lepor MD); Montréal Health Innovations Coordinating Center, Montreal, QC, Canada (N Sainturet PhD, 924 Background Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and coronary disease. We aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. Methods The present study is a phase 3, randomised, double-blind, adaptive, placebo-controlled, multicentre trial. The study was done in Brazil, Canada, Greece, South Africa, Spain, and the USA, and was led by the Montreal Heart Institute. Patients with COVID-19 diagnosed by PCR testing or clinical criteria who were not being treated in hospital were eligible if they were at least 40 years old and had at least one high-risk characteristic. The randomisation list was computer-generated by an unmasked biostatistician, and masked randomisation was centralised and done electronically through an automated interactive web-response system. The allocation sequence was unstratified and used a 1:1 ratio with a blocking schema and block sizes of six. Patients were randomly assigned to receive orally administered colchicine (0·5 mg twice..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit